Share This Page
Suppliers and packagers for APTIVUS
✉ Email this page to a colleague
APTIVUS
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | APTIVUS | tipranavir | CAPSULE;ORAL | 021814 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0003-02 | 120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (0597-0003-02) | 2005-07-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for APTIVUS
APTIVUS (tipranavir) supplier landscape: who manufactures active ingredient, finished dose, and key inputs
Executive summary: Aptivus is tipranavir, a HIV-1 protease inhibitor supplied globally in oral capsule form. The supplier chain is split between (1) active pharmaceutical ingredient (API) production and (2) finished-dose manufacturing, with typical reliance on contract manufacturing organizations (CMOs) for capsule fill and packaging. Public-facing supplier details vary by geography and by strength (capsule) and are reflected in FDA labeling, regulatory filings, and product licensing/wholesaler distribution networks.
What can be stated precisely from available public documentation: no complete, authoritative cross-market list of all “suppliers” (API sites, excipient vendors, capsule/printing systems, and packaging lines) for Aptivus can be produced without using the drug’s specific label-manufacturing section and/or assignment-level regulatory records that enumerate each site.
What companies supply Aptivus (tipranavir) capsules in the US and EU?
Answer: Aptivus distribution is handled by marketing authorization holders and wholesalers; production is performed at specific manufacturing sites named in product labeling and regulatory documents. A reliable supplier list requires identifying the label/manufacturing sites tied to the FDA product and each EU MAH variant.
Which “supplier” categories matter for procurement and IP diligence?
- API manufacturer (tipranavir synthesis and isolation)
- Finished-dose manufacturer (capsule manufacturing, sterilization not applicable, blending, encapsulation, packaging)
- Excipients and capsule components (fill aids, solvents, capsule shells, ink/printing)
- Packaging supplier (bottles, blister packs, desiccants, induction seals)
- Quality systems and testing labs (incoming material QC, in-process controls, release testing)
Why “supplier lists” differ by region
- Aptivus has multiple label presentations and potentially multiple manufacturing transfers over time.
- EU MA variations can route manufacturing to different sites while keeping the same trade name.
- API supply can rotate among synthesis sites without changing the brand.
What manufacturing companies are listed on the Aptivus label (US Orange Book/labeling source)?
Answer: US labeling typically identifies the manufacturer(s) and packager(s) for the specific dosage form. Those entries are the cleanest “supplier” identifiers for regulatory and procurement mapping.
What to look for in the label
- “Manufactured for” / “Distributed by”
- “Manufactured at” (site address)
- “Packaged by” (site address)
- Submission for FDA labeling updates often tracks site transfers.
Result: A definitive supplier list cannot be produced here because the specific Aptivus label/manufacturing entries (manufacturer and site addresses by strength) are not provided in the prompt.
Which suppliers provide tipranavir API versus finished capsules?
Answer: In practice, the supply chain can split:
- API from a specialized API plant
- finished capsule manufacturing from a CMO with encapsulation and bottling lines
How to verify API vs finished-dose sourcing
- API sourcing shows up in DMF-linked references and site-specific manufacturing controls.
- Finished-dose sourcing shows up in labeling and CMC sections for drug product.
Result: Without the drug-product label text (or the specific submission numbers) for Aptivus, a credible API-versus-drug-product supplier mapping cannot be compiled.
What excipients and capsule components suppliers are used for Aptivus?
Answer: Aptivus capsules include typical capsule shell materials (gelatin and/or alternative polymer systems depending on the formulation era) and formulation excipients. Exact vendor names are rarely disclosed publicly; they are usually controlled under CMC and procurement confidentiality.
Procurement-relevant component groups
- Capsule shell grade and specifications
- Printing ink/technology compatible with capsule shell
- Heat/moisture control (desiccant systems in bottles)
- Overfill/blend aids to control dose uniformity
Result: Public data does not provide a complete vendor list of excipients and capsule components for Aptivus.
How does the supplier chain affect generic or biosimilar entry risk for tipranavir?
Answer: Supplier constraints influence manufacturing feasibility, not legal exclusivity. For tipranavir (small-molecule), the generic risk is mainly:
- formulation process replication
- bioequivalence of exposure
- ability to obtain comparable dissolution behavior
- regulatory inspection and batch consistency
What matters for generic procurement and manufacturing
- access to comparable API grade and polymorph control
- control of capsule manufacturing parameters
- consistency of excipient sources when criticality exists
When do supplier changes become visible for Aptivus?
Answer: Supplier changes show up via:
- labeling updates for manufacturing/packaging sites
- NDA supplement records
- inspection outcomes and CMC updates
Common supplier-change triggers
- site capacity expansions or failures
- regulatory remediation
- corporate restructurings
- cost-driven CMO transitions
What patent estate does supplier mapping interact with (manufacturing IP barriers)?
Answer: Supplier changes can be operationally constrained by:
- process patents (API synthesis routes)
- formulation patents (capsule composition and processing)
- method-of-manufacture patents (specific blending/encapsulation steps)
- regulatory exclusivity periods (less common for older small molecules like tipranavir)
Key diligence points for licensing and litigation
- identify whether the site uses a patented process route
- check whether drug-product process patents cover encapsulation parameters
- evaluate freedom-to-operate for both API and finished dose steps
Result: This requires a patent map for tipranavir drug product and API processes, which is not included in the prompt.
Key Takeaways
- “Suppliers for Aptivus” splits into API, drug product (capsules), packaging, and excipient/capsule-component vendors.
- A complete supplier list requires the specific Aptivus label manufacturing/packaging entries and associated regulatory site records.
- Without the label/manufacturing section for Aptivus in the prompt, a precise, named supplier roster cannot be produced without risking factual errors.
FAQs
- Which companies manufacture the tipranavir API used in Aptivus?
- What manufacturers and packagers are named on the Aptivus capsule label by strength?
- Can Aptivus be sourced in blister packs, and which packaging suppliers are used?
- Do excipient source changes impact tipranavir capsule bioequivalence?
- How do manufacturing site transfers show up in FDA labeling for Aptivus?
References (APA)
- [Not provided in the prompt: Aptivus labeling/manufacturing section and FDA/EU regulatory documents.]
More… ↓
